Infrequent or non-response to oral sumatriptan does not predict response to other triptans - Review of four trials

Cephalalgia

Volumn 26, Issue 2, 2006, Pages 98-106

  Dahlof C G H ^a  

^a Gothenburg Migraine Clinic   (Sweden)

Author keywords

Almotriptan; Migraine; Non response; Sumatriptan; Triptans

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; ENCAPSULATION; HUMAN; MIGRAINE; NEUROTOXICITY; PRACTICE GUIDELINE; PREDICTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT;

ADMINISTRATION, ORAL; CLINICAL TRIALS; HUMANS; MIGRAINE DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT FAILURE; TREATMENT OUTCOME; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 33644940000     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2005.01010.x     Document Type: Review

References (49)

1. Rasmussen BK Olesen J Symptomatic and non-symptomatic headaches in a general population Neurology 1992 42 1225 31
2. Stewart WF Lipton RB Celentano DD Reed ML Prevalence of migraine headaches in the United States. Relation to age, income, race, and other socio-demographic factors J Am Med Assoc 1992 267 64 9
3. Stewart WF Shechter A Rasmussen BK Migraine prevalence. A review of population-based studies Neurology 1994 44 Suppl. 4 S17 23
4. Russeil MB Rasmussen BK Thorvaldsen P Olesen J Prevalence and sex-ratio of the subtypes of migraine Int J Epidemiol 1995 24 612 8
5. Dechant KL Clissold SP Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the acute treatment of migraine and cluster headache Drugs 1992 43 776 98
6. Silberstein SD Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 2000 55 754 62
7. Bigal ME Bordini CA Antoniazzi AL Speciali JG The triptan formulations: a critical evaluation Arq Neuropsiquiatr 2003 61 313 20
8. Diener HC Limmroth V Advances in pharmacological treatment of migraine Expert Opin Invest Drugs 2001 10 1831 45
9. Tfelt-Hansen P De Vries P Saxena PR Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy Drugs 2000 60 1259 87
10. Diener HC Pharmacological approaches to migraine J Neural Transm Suppl 2003 64 35 63
11. Tfelt-Hansen P Block G Dahlöf C Diener HC Ferrari MD Goadsby PJ et al. Guidelines for controlled trials of drugs in migraine: second edition Cephalalgia 2000 ; 20: 765 86
12. Dahlöf CG Dodick D Dowson AJ Pascual J How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials Headache 2002 42 99 113
13. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials Cephalalgia 2002 22 633 58
14. Dahlöf CG Sumatriptan: pharmacological basis and clinical results Curr Med Res Opin 2001 17 s35 45
15. Dahlöf CGH Characteristics of different routes of administration. In: Olesen J Ferrari M Humphrey PPA, editors Frontiers in headache research - the triptans: novel drugs for migraine Oxford Oxford University Press 2001 80 90
16. Dahlöf CGH Lipton RB Lines CR Kramer MS Reines SA Polis AB et al. Consistency of pain relief over multiple migraine attacks following treatment with rizatriptan. In: Olesen J Ferrari M Humphrey PPA, editors Frontiers in headache research - the triptans: novel drugs for migraine Oxford Oxford University Press 2001 222 35
17. Dahlöf C Integrating the triptans into clinical practice Curr Opin Neurol 2002 15 317 22
18. Dahlöf C Jones M Davis K Loftus J Salonen R A comparison of preference for and efficacy of tablet formulations of sumatriptan (50 mg and 100 mg), naratriptan (2.5 mg), rizatriptan (10 mg), and zolmitriptan (2.5 mg) in the acute treatment of migraine J Headache Pain 2004 5 115 22
19. Dahlöf C Clinical applications of new therapeutic deliveries in migraine Neurology 2003 61 8 Suppl. 4 S31 4
20. Dodick D Patient perceptions and treatment preferences in migraine management CNS Drugs 2002 1 19 24
21. Kaufman JS Levine I Acute gastric dilatation of stomach during attack of migraine Radiology 1936 27 301 2
22. Volans GN Migraine and drug absorption Clin Pharmacokinet 1978 3 313 8
23. Tokola RA Kangasniemi P Neuvonen PJ Tokola O Tolfenamic acid, metoclopramide, caffeine and their combinations in the treatment of migraine attacks Cephalalgia 1984 4 253 63
24. Tokola RA Neuvonen PJ Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid Br J Clin Pharmacol 1984 17 67 75
25. Dahlöf CG Hargreaves RJ Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies? Cephalalgia 1998 18 593 604
26. Houghton LA Fowler P Keene ON Read NW Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man Aliment Pharmacol Ther 1992 6 685 91
27. Cipolla G Sacco S Crema F Moro E De Ponti F Frigo G Gastric motor effects of triptans: open questions and future perspectives Pharmacol Res 2001 43 205 10
28. Tack J The physiology and the pathophysiology of the gastric accommodation reflex in man Verh K Acad Geneeskd Belg 2000 62 183 207
29. Burstein R Cutrer MF Yarnitsky D The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine Brain 2000 123 1703 9
30. Burstein R Yarnitsky D Goor-Aryeh I Ransil BJ Bajwa ZH An association between migraine and cutaneous allodynia Ann Neurol 2000 47 614 24
31. Burstein R Deconstructing migraine headache into peripheral and central sensitization Pain 2001 89 107 10
32. Burstein R Collins B Jakubowski M Defeating migraine pain with triptans: a race against the development of cutaneous allodynia Ann Neurol 2004 55 19 26
33. Rapoport AM Tepper SJ Bigal ME Sheftell FD The triptan formulations: how to match patients and products CNS Drugs 2003 17 431 47
34. Limmroth V Dowson A Diener HC Dahlöf C Non-oral delivery systems in headache therapy - focus on intranasal delivery Am J Drug Deliv 2004 2 59 68
35. Dodick DW Triptan nonresponder studies: implications for clinical practice Headache 2005 45 156 62
36. Mathew NT Kailasam J Gentry P Chernyshev O Treatment of non-responders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial Headache 2000 40 464 5
37. Färkkilä M Olesen J Dahlöf CGH Stovner LJ ter Bruggen JP Rasmussen S et al Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan Cephalalgia 2003 23 463 71
38. Stark S Spierings ELH McNeal S Putnam GP Bolden-Watson C O'Quinn S Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan Headache 2000 40 513 20
39. Diener HC Gendolla A Gebert I Beneke M Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial Headache 2005
40. Rapoport AM Tepper SJ Triptans are all different Arch Neurol 2001 58 1479 80
41. Saper JR What matters is not the differences between triptans but the differences between patients Arch Neurol 2001 58 1481 2
42. Whitaker JN Triptans for migraine headache: therapeutic progress meets a heterogeneous patient response Arch Neurol 2001 58 1482 3
43. Dahlöf CG Lipton RB McCarroll KA Kramer MS Lines CR Ferrari MD Within-patient consistency of response to rizatriptan for treating migraine Neurology 2000 55 1511 6
44. Jhee SS Shiovitz T Crawford AW Cutler NR Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review Clin Pharmacokinet 2001 40 189 205
45. Ferrari MD Roon KI Lipton RB Goadsby PJ Oral triptans (serotonin 5-HT1B/D agonists) in acute migraine treatment: a meta-analysis of 53 trials Lancet 2001 358 1668 75
46. Gallagher RM Kunkel R Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment Headache 2003 43 36 44
47. Dodick DW Martin V Triptans and CNS side effects: pharmacokinetic and metabolic mechanisms Cephalalgia 2004 24 417 24
48. Pascual J Munoz P Correlation between lipophilicity and triptan outcomes Headache 2005 45 3 6
49. Dodick DW Triptans and chest symptoms: the role of pulmonary vasoconstriction Cephalalgia 2004 24 298 304